Pure Global AI
NCT05899699Not yet recruiting

Effect of New Topical Preparation for Treatment of Acne Vulgaris

Potential Combination Topical Therapy of Acne Vulgaris: a Randomized Controlled Trial Comparing Efficacy of DAP/FLU Micro-emulsion vs. Standard Therapy of Adapalene.
Mansoura UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Acne Vulgaris
Drug/Device/Intervention
DAP-FLU ME
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mansoura University
Location
Mansoura, Egypt
Timeline & enrollment
Phase
Phase 2
Start date
Jun 05, 2023
End date
Oct 01, 2023
Enrollment
20 participants
Primary outcome

Michaelson's acne severity index (ASI),Safety assessment by the recording of patient-reported adverse events

Summary

The investigators propose a randomized, double-blind control trial study to evaluate the
 efficacy and safety of the optimized topical combination ME of the investigated drugs in the
 treatment of acne vulgaris containing DAP-FLU in comparison with standard therapy of
 Adapalene at Mansoura University Dermatology and Andrology Outpatient Clinic.

ICD-10 classifications
Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05899699
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05899699 through Pure Global AI's free database. This Phase 2 trial is sponsored by Mansoura University and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.